Table 1.
Pretreatment Characteristics by Study (n=1736)
| Characteristic | 9003 n (%) | 9111 n (%) | 9703 n (%) | Total n (%) |
|---|---|---|---|---|
| Eligible | 1021 | 483 | 232 | 1736 |
| Age (years) | ||||
| Mean | 60.5 | 59.0 | 57.5 | 59.7 |
| Range | 30–90 | 29–79 | 21–83 | 21–90 |
| Median | 61 | 59 | 56 | 60 |
| Age < 60 | 463 (45%) | 246 (51%) | 139 (60%) | 848 (49%) |
| Age ≥ 60 | 558 (55%) | 237 (49%) | 93 (40%) | 888 (51%) |
| Gender | ||||
| Female | 214 (21%) | 104 (22%) | 46 (20%) | 364 (21%) |
| Male | 807 (79%) | 379 (78%) | 186 (80%) | 1372 (79%) |
| Race | ||||
| White | 742 (73%) | 369 (76%) | 172 (74%) | 1283 (74%) |
| Non-White | 279 (27%) | 114 (24%) | 60 (26%) | 453 (26%) |
| Marital Status | ||||
| Partnered/other live-in relationship | 505 (49%) | 282 (58%) | 134 (58%) | 921 (53%) |
| Unpartnered/divorced/separated/widowed | 516 (51%) | 201 (42%) | 98 (42%) | 815 (47%) |
| T-Stage | ||||
| T1–T3 | 724 (71%) | 436 (90%) | 136 (59%) | 1296 (75%) |
| T4 | 297 (29%) | 47 (10%) | 96 (41%) | 440 (25%) |
| N –Stage | ||||
| N0-N1-N2a | 535 (52%) | 354 (73%) | 84 (36%) | 973 (56%) |
| N2b-N2c-N3 | 486 (48%) | 129 (27%) | 148 (64%) | 763 (44%) |
| Primary Site | ||||
| Orpharynx | 615 (60%) | 0 (0%) | 153 (66%) | 768 (44%) |
| Others | 406 (40%) | 483 (100%) | 79 (34%) | 968 (56%) |
| KPS | ||||
| 60–80 | 640 (63%) | 357 (74%) | 151 (65%) | 1148 (66%) |
| 90–100 | 381 (37%) | 126 (26%) | 81 (35%) | 588 (34%) |
| Chemotherapy (CT) Usage | ||||
| RT + any CT | 0 (0%) | 321 (66%) | 232 (100%) | 553 (32%) |
| RT alone | 1021 (100%) | 162 (34%) | 0 (0%) | 1183 (68%) |
| Altered RT Fraction (HFX) | ||||
| Yes | 516 (51%) | 0 (0%) | 0 (0%) | 516 (30%) |
| No | 505 (49%) | 483 (100%) | 232 (100%) | 1220 (70%) |